tiprankstipranks
Advertisement
Advertisement
Buy Rating on Krystal Biotech Driven by Vyjuvek’s Global Momentum and Upside from Enhanced NK and Corneal Abrasion Pipeline
PremiumRatingsBuy Rating on Krystal Biotech Driven by Vyjuvek’s Global Momentum and Upside from Enhanced NK and Corneal Abrasion Pipeline
1M ago
Krystal Biotech: Transitioning to Global Growth as De‑Risked HSV‑1 Gene Therapy Platform Advances Toward Pivotal Stages
Premium
Ratings
Krystal Biotech: Transitioning to Global Growth as De‑Risked HSV‑1 Gene Therapy Platform Advances Toward Pivotal Stages
1M ago
Krystal Biotech: Strong Vyjuvek Performance, De‑Risked Gene Therapy Pipeline, and International Expansion Underscore Buy Rating and $318 Target
Premium
Ratings
Krystal Biotech: Strong Vyjuvek Performance, De‑Risked Gene Therapy Pipeline, and International Expansion Underscore Buy Rating and $318 Target
1M ago
Krystal Biotech sees FY26 non-GAAP R&D, SG&A expense $175M-$195M
PremiumThe FlyKrystal Biotech sees FY26 non-GAAP R&D, SG&A expense $175M-$195M
1M ago
Krystal Biotech reports Q4 EPS $1.70, consensus $1.61
Premium
The Fly
Krystal Biotech reports Q4 EPS $1.70, consensus $1.61
1M ago
Krystal Biotech, Inc. (KRYS) Q4 Earnings Cheat Sheet
Premium
Pre-Earnings
Krystal Biotech, Inc. (KRYS) Q4 Earnings Cheat Sheet
1M ago
Krystal Biotech outlines rare disease growth strategy update
PremiumCompany AnnouncementsKrystal Biotech outlines rare disease growth strategy update
3M ago
Krystal Biotech price target raised to $336 from $320 at Citi
Premium
The Fly
Krystal Biotech price target raised to $336 from $320 at Citi
3M ago
Krystal Biotech price target raised to $306 from $202 at TD Cowen
Premium
The Fly
Krystal Biotech price target raised to $306 from $202 at TD Cowen
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100